CLEAR CELL RENAL CELL CARCINOMA

This study tests a combination of two drugs—nivolumab and a radioactive antibody called 177Lu-girentuximab—for people with advanced clear cell kidney cancer that has a specific protein (CAIX). The goal is to see if the combination is safe and can shrink tumors. About 9 participan…

This early-stage trial tests whether adding camu camu, a prebiotic berry, to standard immunotherapy (nivolumab and ipilimumab) can improve treatment for advanced kidney cancer. About 31 people with metastatic clear-cell or sarcomatoid kidney cancer will receive the combination. T…

This early-phase study looks at how safe and effective immunotherapy drugs (nivolumab alone or with bevacizumab or ipilimumab) are when given before surgery to people with kidney cancer that has spread. About 104 participants will receive these treatments to see how the body reac…

This study tested two drugs, pazopanib and bevacizumab, given in turns to people with advanced kidney cancer that had spread. The goal was to find the best dose and see if the combination could control tumor growth. 51 patients took part, and the study focused on safety and how l…

This phase 3 trial tests whether adding the drug cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will take part. The goal is to see if the combination wor…

This study tests a personalized approach to treating advanced clear cell kidney cancer by adjusting doses of immunotherapy (pembrolizumab) and a targeted drug (axitinib) based on tumor response. It aims to see if this flexible dosing is feasible and helps control the disease long…

This early-phase study tests two or three drugs together (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced cancers of the urinary and genital systems that have spread. The main goals are to find the safest dose and understand side effects. About 152 adul…

This study tests whether adding a selenium supplement (SLM) to two standard cancer drugs (axitinib and pembrolizumab) is safe and effective for people with advanced clear cell kidney cancer. About 55 participants will receive the combination therapy. The goal is to see if the sup…

This study tests whether giving the drug cabozantinib before surgery can shrink tumors in people with locally advanced kidney cancer. About 22 participants will receive the drug for a short time before their operation. The goal is to see if this approach helps control the disease…

This study tests whether adding an experimental drug (anti-OX40 antibody) to a standard targeted therapy (axitinib) can help control advanced kidney cancer that has spread. About 62 adults whose cancer worsened after prior immunotherapy will receive either the combination or axit…

This study tests a drug called adavosertib in 18 adults with advanced solid tumors that lack the SETD2 gene. The drug works by blocking enzymes that help cancer cells grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.

This study tests a combination of two drugs, cadonilimab and lenvatinib, in people with advanced clear cell kidney cancer whose disease got worse after initial immunotherapy. The goal is to see if this combo can shrink tumors or stop them from growing. About 28 adults will take p…

This study tests whether adding a radioactive drug (radium-223) to the usual treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 adults with any type of kidney cancer and bone metastases will be randomly assigned to receive ca…

This study tests if a subcutaneous (under the skin) injection of the drug nivolumab works as well as the standard intravenous (IV) infusion for people with advanced or metastatic clear cell renal cell carcinoma, a type of kidney cancer. About 681 participants who have already rec…

This early-stage study tests a new drug called NYM096 for people with advanced clear cell kidney cancer that has spread. The drug is designed to find and treat cancer cells using a special imaging scan and targeted radiation. The study has two parts: first, using a low dose to se…

This study tests whether the drug pazopanib can delay or prevent kidney cancer from returning in patients who have had all visible tumors removed by surgery. About 129 adults with advanced kidney cancer that spread to other parts of the body but showed no signs of disease after s…

This study tested the drug axitinib in 22 people with a type of kidney cancer (clear cell renal cell carcinoma) who needed surgery but had complex tumors that made it hard to remove only the cancerous part. The goal was to see if taking axitinib before surgery could shrink the tu…

This study tests a drug called ceralasertib, either alone or combined with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, endometrial, and prostate cancers. The goal is to see if these combinations can shrink tumors or slow their gr…

This study tests a combination of two drugs—entinostat and aldesleukin—for people with kidney cancer that has spread. The goal is to find the safest dose and see if the combo can shrink tumors. About 47 adults with clear cell kidney cancer are taking part.

This study collects blood, tissue, and urine samples from 589 adults with different types of kidney or urinary tract tumors, plus healthy controls. Researchers use advanced DNA sequencing to find unique markers (methylated DNA) that could help detect these cancers earlier. The go…

This study was designed to see if a special PET/CT scan using piflufolastat F 18 could better find kidney cancer that has spread beyond the kidney. It planned to include adults with suspected or high-risk metastatic clear cell renal cell carcinoma. The study was withdrawn before …

This study aims to understand how kidney tumors differ from one another in people with von Hippel-Lindau (VHL) syndrome, a rare genetic condition. Researchers will use advanced imaging, multiple tumor biopsies, and lab-grown tumor models to map these differences. The goal is to l…